<DOC>
	<DOCNO>NCT01094769</DOCNO>
	<brief_summary>The purpose study determine whether moxonidine effective reduce urine albumin level patient diabetic kidney disease .</brief_summary>
	<brief_title>Sympathetic Nervous System Inhibition Treatment Diabetic Kidney Disease</brief_title>
	<detailed_description>This study investigate effect moxonidine lower urine albumin excretion limit damage kidney patient diabetic nephropathy . Reducing urine albumin excretion type 2 diabetic patient indicator successful treatment . Previous study show drug work similar fashion moxonidine ( intervene sympathetic nervous system ) effective reduce amount albumin urine associate long term renal cardiovascular protection .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Moxonidine</mesh_term>
	<criteria>age : 1875 year diabetic nephropathy define mean three consecutive early morning urinary albumincreatinine ratio ( UACR ) &gt; 300mg per gram , &gt; 200mg per gram patient receive therapy target blockade RAS nondiabetic kidney disease UACR 3500mg per gram , estimate glomerular filtration rate le 30ml/min/1.73m2 . chronic urinary tract infection . severe hypertension heart failure NYHA class IIIV major cardiovascular disease within previous 6 month leave ventricular ejection fraction &lt; 55 %</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>